Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.
COVID-19
COVID-19 vaccines
Malignancy
SARS-CoV-2
anticancer treatment
cancer patients
Journal
Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
13
10
2021
medline:
27
1
2022
entrez:
12
10
2021
Statut:
ppublish
Résumé
To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients. 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA. Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers. The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.
Identifiants
pubmed: 34634986
doi: 10.1080/07357907.2021.1992420
pmc: PMC8567287
doi:
Substances chimiques
COVID-19 Vaccines
0
SARS-CoV-2 inactivated vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM